arrow
J

Jerzy Krzysztof Wranicz

Medical University of Lodz
H指数:23
被引数:2,958

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase

锆硅酸钠、高钾血症及螺内酯优化在射血分数降低的心力衰竭中的应用:REALIZE-K开放标签的预实验阶段

2025-08-200
OAAI
Preventing chronic heart failure and improving survival after transcatheter aortic valve implantation in patients with the need for permanent pacemaker implantation: Rationale and design of the physiologic cardiac pacing to prevent left ventricular dysfunction post transcatheter aortic valve implantation (PACE-4-TAVI) trial

预防永久起搏器植入需求患者的经导管主动脉瓣植入术后慢性心力衰竭并改善生存:生理性心脏起搏以预防经导管主动脉瓣植入术后左心室功能障碍(PACE-4-TAVI)试验的合理性与设计

2025-04-300
OA
Benefits of upgrading right ventricular to biventricular pacing in heart failure patients with atrial fibrillation

将右心室起搏升级为双心室起搏对患有房颤的心力衰竭患者的益处

2024-07-090
PRE
Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial

右心室起搏对心力衰竭心脏再同步治疗的升级: 一项随机试验

2023-08-2628
OAAI
Ability to remotely monitor atrial high-rate episodes using a single-chamber implantable cardioverter-defibrillator with a floating atrial sensing dipole
2023-04-115
OAAI
Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST-CRT Upgrade trial
2022-07-2213
OAAI
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

SGLT2抑制剂恩格列净在急性心力衰竭住院患者中的应用: 一项跨国随机试验

2022-02-28498
OAAI
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
2020-12-22137
PRE